RhGh did not consistently affect blood pressure or bone mineral density .
RhGH consistently improved quality of life ( QoL ) parameters reflected in AGHDA-scores .
Conclusion RhGH replacement in elderly subjects with GHD  decreases LDL cholesterol levels and improves QoL , but the effects on other parameters are not unequivocal .
There were no data on the efficacy and safety  of rhGH treatment in octogenarians with GHD
Context Recombinant human GH ( rhGH ) is prescribed for the treatment of adults with GH deficiency ( GHD ) .
However , conflicting data are available on the efficacy of rhGH treatment in elderly GHD patients .
Objective To assess the efficacy of rhGH treatment in elderly GHD subjects .
Plasma Lipoproteins and Apolipoproteins as Predictors of Cardiovascular Risk and Treatment Benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)
Background — Statins are important in vascular disease prevention in the elderly . However , the best method of selecting older patients for treatment is uncertain . We assessed the role of plasma lipoproteins as predictors of risk and of treatment benefit in the PROspect i ve Study of Pravastatin in the Elderly at Risk ( PROSPER ) . Method and Results — The association of LDLc and HDLc with risk was examined in the 5804 70- to 82-year-old subjects of PROSPER .  Baseline LDLc showed no relation to risk of the primary end point in the placebo group ( P=0.27 ) , nor did on-treatment LDLc in the pravastatin group ( P=0.12 ) . HDLc was inversely associated with risk in subjects on placebo ( P=0.0019 ) but not in those on pravastatin ( P=0.24 ) . Risk reduction on pravastatin treatment was unrelated to baseline LDLc ( P=0.38 ) but exhibited a significant interaction with HDLc ( P=0.012 ) . Subjects in the lowest 2 quintiles of HDLc ( < 1.15 mmol/L ) had a risk reduction of 33 % ( hazard ratio , 0.67 ; 95 % confidence limits , 0.55 , 0.81 ; P<0.0001 ) , whereas those with higher HDLc showed no benefit ( RR , 1.06 ; 95 % confidence limits , 0.88 , 1.27 ; P=0.53 ) . During follow-up , there was no relation between achieved level of LDLc or HDLc and risk . However , the change in the LDLc/HDLc ratio on statin treatment appeared to account for the effects of therapy . Conclusions — In people > 70 years old , HDLc appears to be a key predictor of risk and of treatment benefit . Findings in PROSPER suggest that statin therapy could usefully be targeted to those with HDLc < 1.15 mmol/L or an LDLc/HDLc ratio > 3.3
RhGh did not consistently affect blood pressure or bone mineral density .
RhGH consistently improved quality of life ( QoL ) parameters reflected in AGHDA-scores .
Conclusion RhGH replacement in elderly subjects with GHD  decreases LDL cholesterol levels and improves QoL , but the effects on other parameters are not unequivocal .
There were no data on the efficacy and safety  of rhGH treatment in octogenarians with GHD
Context Recombinant human GH ( rhGH ) is prescribed for the treatment of adults with GH deficiency ( GHD ) .
However , conflicting data are available on the efficacy of rhGH treatment in elderly GHD patients .
Objective To assess the efficacy of rhGH treatment in elderly GHD subjects .